Table 1 Characteristics of patients enrolled into IMPACT/COMPACT (n = 1893)
Patients enrolled | Patients enrolled | Patients profiled | Patients profiled enrolled on any therapeutic trials | Patients profiled enrolled on genotype-matched trials |
|---|---|---|---|---|
Median age (range) | 59 (18–89) | 58 (18–89) | 58 (18–81) | 58 (24–81) |
Female/Male | 1303/590 (59 %)/(31 %) | 1166/479 (71 %)/(29 %) | 205/72 (74 %)/(26 %) | 64/25 (72 %)/(28 %) |
Median lines of prior treatment (range) | 2 (1–18) | 2 (1–18) | 2 (1–16) | 2 (1–11) |
ECOG performance status (0/1/2) | 43 %/56 %/<1 % | 44 %/55 %/<1 % | 78 %/22 %/0 % | 78 %/22 %/0 % |
Median time from collection of archival tumor sample to profiling report in years (range) | 1.6 (0.1-24.9) | 1.7 (0.1-18.9) | 1.9 (0.1-18.9) | |
Primary lesion/Metastatic lesion profiled | 1080/560 | 193/84 | 66/23 | |
(66 %)/(34 %) | (70 %)/(30 %) | (74 %)/(26 %) | ||
Tumor types | ||||
Breast | 341 (18 %) | 310 (19 %) | 41/310 (13 %) | 19/310 (6 %) |
Colorectal | 326 (17 %) | 299 (18 %) | 38/299 (13 %) | 18/299 (6 %) |
Gynecological | 430 (23 %) | 405 (25 %) | 80/405 (20 %) | 20/405 (5 %) |
Lung | 339 (18 %) | 256 (16 %) | 43/256 (17 %) | 18/256 (7 %) |
Genitourinary | 92 (5 %) | 74 (5 %) | 9/74 (12 %) | 4/74 (5 %) |
Pancreatobiliary | 151 (8 %) | 104 (6 %) | 9/104 (9 %) | 1/104 (1 %) |
Upper aerodigestive | 115 (6 %) | 102 (6 %) | 8/102 (8 %) | 2/102 (2 %) |
Other | 99 (5 %) | 81 (5 %) | 17/81 (21 %) | 2/81 (2 %) |
TOTAL | 1893 | 1640 | 245/1640 (15 %) | 84/1640 (5 %) |